3,338
Views
11
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States

, , , , , , , & show all
Pages 442-447 | Received 09 Aug 2019, Accepted 12 Dec 2019, Published online: 29 Jan 2020

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.